Everything below concerns GRF(1-29). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
By stimulating (or charging) genetically engineered roundworm mitochondria with light, researchers show that halting the decline in mitochondrial membrane potential can slow aging (30 Dec). Researchers report the development of 3D-printed flexible paper-thin organic photovoltaics. 12 December – Scientists describe a new method to break up so-called "forever chemicals" by infusing contaminated water with hydrogen, then blasting it with high-energy, short-wavelength ultraviolet light. 13 December The Newborn Genomes Programme is announced by the UK government. It will conduct whole genome sequencing of 100,000 newborns, the largest study of its kind in the world, to aid research into the diagnosis and treatment of rare genetic conditions. In a major milestone for the field, scientists at the National Ignition Facility report a net energy gain in the development of fusion power. COVID-19 pandemic: A study finds that the BQ and XBB subvariants of SARS-CoV-2 are "barely susceptible to neutralization" by vaccines, including the new Omicron boosters. Key antibody drugs, Evusheld and bebtelovimab, are "completely inactive" against the new subvariants. This could result in a surge of breakthrough infections and reinfections, according to the study team, although the vaccines hold up against severe disease. A study systematically assesses advice given by professional general practitioners, typically in the form of verbal-only consultation, for weight-loss to obese patients.
== Comparison of somatostatin receptor agonists and antagonists in radiolabelling == Agonists of the somatostatin receptor had been long established as an imaging agent, with the first agonist Ga-DOTATOC coming out in 2001, which is based on a radiolabeled somatostatin receptor agonist drug octreotide, and further developments were based on its structure. Agonists share the characteristic of being uptaken into tumor cells, and degraded intracellularly. Antagonists, while not widely absorbed into the tumor cells, can bind to a wider range of receptors as they can bind to the receptors regardless if the receptors are activated or inactivated. They thus are more sensitive to neuroendocrine tumors. Another study noted the antagonists showed lowered internalization into tumors, cleared from the blood quickly, and had a higher binding to tumors, which were noted to be properties benefitting its use over agonists in detecting metastatic tumors. A head-to-head study of the gallium-containing compounds, where the Ga-NODAGA-JR11 antagonist and Ga-DOTATOC agonist are directly compared, showed that Ga-NODAGA-JR11 had a higher hepatic metastatic tumor detection rate and lesion sensitivity than Ga-DOTATOC. Another head-to-head study of lutetium containing compound found the antagonist Lu-DOTA-JR11 bound with the receptors more quickly, had a longer retention time, and unbound more slowly than the Lu-DOTA-TATE agonist.
NHS England confirms that data managed by Synnovis, an organisation that manages blood tests, was stolen in a cyberattack on 3 June. Flights are restored at Manchester Airport, but with delays for passengers scheduled to travel the previous day. Julian Assange leaves the UK after five years held at Belmarsh Prison after reaching a deal with the US to plead guilty to one charge under the Espionage Act instead of the original 18. He will be returned to his native Australia. 25 June 2024 United Kingdom general election betting scandal: The Conservative Party withdraws its support for Craig Williams and Laura Saunders as election candidates. Cabinet minister Alister Jack, who previously said he had won £2,100 by betting on the date of the election, then said he was joking, issues a statement in which he says he did not place a bet on the election. The Metropolitan Police confirms that the Gambling Commission are investigating a further five police officers for placing bets on the date of the election. Russell George, the Senedd member for Montgomeryshire, becomes the fifth Conservative politician to be investigated by the Gambling Commission for election betting. Labour suspends Kevin Craig, their candidate for Central Suffolk and North Ipswich, after the Gambling Commission launches an unrelated investigation into him for placing a bet against himself losing in his constituency. Police arrest four men who entered the grounds of Kirby Sigston Manor, the constituency home of Rishi Sunak.
=== Birds and reptiles === The epidermis of birds and reptiles is closer to that of mammals, with a layer of dead keratin-filled cells at the surface, to help reduce water loss. A similar pattern is also seen in some of the more terrestrial amphibians such as toads. In these animals, there is no clear differentiation of the epidermis into distinct layers initially, as occurs in humans, with the change in cell type being relatively gradual. The mammalian epidermis always possesses at least a stratum germinativum and stratum corneum, but the other intermediate layers found in humans are not always distinguishable. Hair is a distinctive feature of mammalian skin, while feathers are (at least among living species) similarly unique to birds. Birds and reptiles have relatively few skin glands, although there may be a few structures for specific purposes, such as pheromone-secreting cells in some reptiles, or the uropygial gland of most birds.
In both children and adults, there is an association between television viewing time and the risk of obesity. Increased media exposure increases the rate of childhood obesity, with rates increasing proportionally to time spent watching television.
Sources: en.wikipedia.org
== Trivial names of some resorcinolic lipids == olivetol persoonol grevillol ardisinol I ardisinol II adipostatin A adipostatin B bilobol hexylresorcinol hydrobilobol cardol rucinol irisresorcinol panosialin stemphol R-leprosol α-leprosol merulinic acid xenognosin
==== Treatment ==== Treatment should resolve reversible pulpitis; early treating may help prevent irreversible pulpitis Follow-up required to determine whether the reversible pulpitis has returned to a normal status
== Initial proposal and development == Neutron capture therapy (NCT) was first proposed in the literature in 1936 by Gordon L. Locher, who observed that isotopes with large neutron capture cross sections, such as boron-10, could be accumulated in cancerous tissue and bombarded with thermal neutrons to induce destruction of the cancerous cells. Boron was seen as a qualified candidate for NCT because the alpha particles of 10B (4He2+), produced from boron's reaction with a neutron beam, can induce apoptosis with a relatively tight travel radius about the diameter of a cell. The proposition was that boron-10 containing delivery agents would take advantage of properties of cancer cells that are not present in normal tissue cells, such as overexpression of certain enzymes or the lack of blood brain barrier. This idea was attractive because it had the potential to be more selective than traditional chemo- and radiotherapies. However, BNCT requires a neutron beam to act as a source of thermal neutrons and a suitable boron-delivery agent; neither was available at the time of Locher's suggestion. Therefore, it was not until the 1950s, when nuclear reactors were available, that Locher's proposal was put into practice. Since neutrons have a low penetration range, only about 2–3 cm below the skin's surface, BNCT was proposed for head and neck cancers.
In the late autumn of 1980, having spent several years on spiritual pursuits and then gradually returning to music (including playing guitar for David Bowie, Brian Eno, Peter Gabriel and Daryl Hall; pursuing an experimental solo career; and leading the instrumental new wave band The League of Gentlemen), Fripp decided to form a new "first division" rock group. Having recruited Bruford as drummer, Fripp then asked the American singer and guitarist Adrian Belew, who had previously played with Bowie and Frank Zappa, to join; this was the first time Fripp would actively seek collaboration with another guitarist in a band, and therefore indicative of his desire to create something unlike any of his previous work. After touring with Talking Heads, Belew agreed to join and also become the band's lyricist. Bruford's suggestion of bassist Jeff Berlin of Bruford was rejected as Fripp thought his playing was "too busy", so auditions were held in New York; on the third day, Fripp left after roughly three auditions, only to return several hours later with session bassist Tony Levin (who got the job after playing a single chorus of "Red"). Fripp later confessed that, had he known that Levin (whom Fripp had played with in Peter Gabriel's group) was available and interested, he would have selected him without holding auditions. Fripp named the new quartet Discipline, and they went to England to rehearse and write new material. They made their live debut at Moles Club in Bath, Somerset on 30 April 1981, and completed a short UK tour supported by the Lounge Lizards.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.